Physician profile
Amber Billiard
NPI 1629844030
$1,684.03
in general payments reported to CMS, 2019-2025
20 companies · $1,143 in 2025
The $1,143 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $17.18 · 2024: $524 · 2025: $1,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,684.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $331.83 | 2025 | Iqirvo |
| Abbvie INC. | $287.91 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $217.98 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $129.72 | 2024-2025 | Mounjaro, Zepbound, Omvoh |
| Ardelyx, INC. | $122.05 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $97.54 | 2025 | Wegovy |
| Janssen Biotech, INC. | $68.74 | 2025 | Tremfya |
| Sumitomo Pharma America, INC. | $54.98 | 2024-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.86 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $47.24 | 2024-2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $45.49 | 2025 | Zenpep |
| Dexcom, INC. | $37.04 | 2024-2025 | Dexcom G6 Transmitter |
| Celltrion USA INC. | $34.31 | 2025 | Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.80 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $28.72 | 2024 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $25.89 | 2025 | Voquezna |
| Lundbeck LLC | $21.65 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $19.17 | 2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $17.18 | 2023 | Austedo Xr |
| Intercept Pharmaceuticals, INC. | $15.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Billiard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.